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Background: Liposomal formulations of anthracyclines appear to have favorable toxicity profile when compared
with conventional anthracyclines in elderly, high risk cardiac patients and patients with prior use of anthracyclines.
Randomized controlled trials have evaluated the efficacy and safety profile of liposomal formulations with
conventional anthracyclines. Our aim is to evaluate the adverse effects and quantify the relative safety profile of the
liposomal and conventional anthracyclines through meta-analysis of the published randomized trials.
Methods: We conducted a broad search strategy of major electronic databases. We performed a meta- analysis of
adverse effects on randomized controlled trials comparing liposomal formulation and conventional anthracyclines
on different tumors. The primary outcome was the adverse effects including congestive heart failure (CHF),
hematological toxicity, palmar-plantar erythrodysthesias (PPE), alopecia, nausea and vomiting. The odds ratios of the
adverse effects were calculated separately and the overall odds ratio of the pooled data was calculated.
Results: We identified nine randomized controlled trials comparing liposomal formulations and conventional
anthracyclines. The study included 2220 patients, of which1112 patients were treated with liposomal formulations
and 1108 were treated with conventional anthracyclines. We found that the liposomal formulations have low
incidence of CHF(OR 0.34, 95% CI, 0.24–0.47), alopecia (OR 0.0.25, 95% CI, 0.0.10-0.62), neutropenia (OR 0.62, 95% CI,
0.45- 0.85),(OR 0.89, 95% CI, 0.71-1.125), and thrombocytopenia (OR 0.87, 95% CI, 0.61-1.25). The incidence of PPE
was similar in both arms (OR 1.08, 95% CI, 0.11- 10.30).
Conclusions: Liposomal doxorubicin and pegylated liposomal doxorubicin demonstrated favorable toxicity profiles
with better cardiac safety and less myelosuppression, alopecia, nausea and vomiting compared with the
conventional anthracyclines. The better therapeutic index of liposomal anthracyclines without compromising the
efficacy makes it a favorable choice over conventional anthracyclines in elderly patients, patients with risk factors for
cardiac disease and patients with prior use of anthracyclines.Introduction
Anthracyclines have become one of the most important
drugs for the treatment of both hematological and solid
tumors [1-3]. Conventional anthracyclines have a rela-
tively low therapeutic index [4]. The risk of cardiotoxi-
city increases with higher cumulative doses of
anthracyclines [4-7]. It is recommended that the cumu-
lative life time dose of doxorubicin should not exceed* Correspondence: delong_liu@nymc.edu.
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reproduction in any medium, provided the or450–500 mg/m2. Anthracycline cardiotoxicity is an issue
not only when it is administered as a single agent, but
also when it is combined with other agents such as tras-
tuzumab, which is a cardio toxic agent by itself [8]. The
mechanisms for cardiotoxicity are mainly due to the de-
velopment of cardiomyopathy as the result of free radical
damage to the myocytes. The toxicity increases with
high peak plasma anthracycline levels [9]. Repeated
damage to the mitochondria of myocytes by the free
radicals is believed to contribute to cumulative cardio-
myopathy [10]. Several liposomal formulations of
anthracyclines have been developed to increase the
therapeutic index of anthracyclines.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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designed to reduce the toxicity of doxorubicin while pre-
serving its antitumor efficacy by altering its tissue distri-
bution and pharmacokinetics. Intravenously injected
liposomes cannot escape the vascular space in sites that
have tight capillary junctions, such as the heart muscle
and gastrointestinal tract. The liposomes generally exit
the circulation in tissues and organs lined with cells that
are not tightly joined (fenestrated) or areas where capil-
laries are disrupted by inflammation or tumor growth.
Thus, liposomes should preferentially direct doxorubicin
away from sites of potential toxicity, but leave the tumor
exposed [11]. Liposomal doxorubicin was associated
with significantly less cardiac and gastrointestinal tox-
icity, while antitumor efficacy was at least comparable to
that of the parent molecule [12,13].
Doxil/Caelyx is a Pegylated (polyethylene glycol coated)
liposome-encapsulated (PLD) form of doxorubicin
[4,7,14]. Doxil has preferential concentration in the skin
because of the polyethylene glycol coating. The main
dose limiting side effects associated with Doxil is the pal-
mar plantar erythrodysesthesia (PPE), otherwise known
as hand-foot syndrome. Following administration of
Doxil, small amounts of the drug can leak from capillar-
ies in the palms of the hands and soles of the feet. The
result of this leakage is redness, tenderness, and peeling
of the skin that can be uncomfortable and even painful.
The prevalence of this side effect limits the Doxil dose
that can be given as compared with doxorubicin in the
same treatment regimen. Outside the United States,
Doxil is known as Caelyx.
Myocet is a non-pegylated liposomal doxorubicin which
is approved in Europe and Canada for treatment of meta-
static breast cancer in combination with cyclophospha-
mide. The rationale behind its design is similar to Doxil
[15-20]. Unlike Doxil, the myocet liposome does not have
a polyethylene glycol coating and therefore does not result
in the same prevalence of Hand-Foot Syndrome. The
minimization of this side effect may allow 1: 1 substitution
with doxorubicin in the same treatment regimen, thereby
improving safety with no loss of efficacy.
DaunoXomeW is a non-pegylated liposomal daunorubi-
cin which is indicated in U.S for the first line treatment
of Advanced AIDS-related Kaposi’s sarcoma [4].
Randomized trials comparing liposomal anthracyclines
with conventional anthracyclines invariably present simi-
lar or higher efficacy with the liposomal anthracyclines.
We performed a meta-analysis from nine randomized
controlled trials of various tumors comparing the out-
come and the adverse effects of conventional anthracy-
clines and liposome encapsulated or pegylated liposomal
anthracyclines. To our knowledge this is the first meta-
analysis comparing the safety of the conventional anthra-
cyclines and the liposome encapsulated anthracyclines.Methods
We used a broad search strategy with special emphasis
on randomized controlled trials. We used a variety of
electronic databases, including MEDLINE via Pub MED,
Ovid, and the Cochrane library.
First we identified key terms of the study drugs “lipo-
somal doxorubicin”, “Doxil” “Myocet”, “Doxorubicin”,
“Daunorubicin”, “Epirubicin”,“Mitoxantrone”,and “Idaru-
bicin”. The key word “liposomal doxorubicin” compared
with “Doxorubicin” was searched using the MeSH sub-
headings without any language barrier. The searches
were combined with the key word search “randomized
controlled trials”. 480 related articles were found, but
only randomized controlled trials comparing liposomal
doxorubicin and conventional anthracycline were
selected for the meta-analysis. The selected randomized
articles were again searched for related topics on the
Pub MED database. We also searched unpublished stud-
ies with results through ‘clinical trials.gov’ and the
American Society of Clinical Oncology (ASCO) website.
We supplemented the searches by reviewing the bibliog-
raphies of key papers.
Eligibility criteria
All randomized controlled trials that compared the effi-
cacy of the liposome encapsulated doxorubicin with the
conventional anthracyclines on any cancer with or with-
out other chemotherapy were considered eligible for the
analysis. The randomized controlled trials on pegylated
liposomal doxorubicin (DoxilW/CAELYX™), non-pegylated
liposomal doxorubicin (Myocet), and liposomal Dauno-
rubicin (DaunoXome) pooled for the meta-analysis, irre-
spective of tumor types and stages. The controlled arms
must include one of the conventional anthracyclines,
epirubicin, daunorubicin, doxorubicin, idarubicin and
mitoxantrone.
Exclusion criteria
Non randomized trials were excluded. Randomized con-
trolled trials with two different anthracyclines, but nei-
ther of them are a liposomal anthracycline were also
excluded. Incomplete ongoing randomized trials with no
published results were excluded as well.
Data extraction
The following information about each trial was
recorded: first author, journal name, year of publica-
tion, number of patients assigned, median age of the
patients in each study, diagnosis, drug combinations
and dose of treatment and the cumulative dose of
anthracyclines. The adverse effects of the liposomal
and conventional anthracyclines were analyzed in two
arms. The variables for the adverse effects include car-
diac toxicity, hematology toxicity, hand-foot syndrome
















1996 37 37 AIDS-KS 232 116 111 Doxorubicin L dauno-40 mg/m2Doxo-10 mg/m2 Lipo- Dauno
Northfelt
et al. [23]
1998 36 38 AIDS-KS 258 133 125 Doxorubicin PLD-20 mg/m2D-20 mg/m2 PLD
Judson et al.
[24]
2000 52 52 Metastatic
soft tissue
sarcoma
94 50 44 Doxorubicin PLD-50 mg/m2D- 75 mg/m2 PLD (CAELYX)
Harris et al.
[8]





2001 55 54 MBC 297 142 155 Doxorubicin LED-60 mg/m2Doxo-60 mg/m2 Myocet
O’Brien et al.
[14]




2003 66 65 MM 259 132 127 Doxorubicin doxil-40 mgdoxo-9 mg/m2 Doxil bolus
Chan et al. [26] 2004 54 54 MBC 160 80 80 Epirubicin LD-75 mg/m2D-75 mg/m2 Myocet
Rifkin et al. [27] 2005 60 60 MM 192 97 95 Doxorubicin Doxil-40 mgDoxo-9 mg/m2 Doxil
Abbreviations: AIDS-KS: Acquired immune deficiency syndrome- Kaposi Sarcoma; D: Doxorubicin; LD: Liposomal Doxorubicin; L Dauno: Liposomal Daunorubicin;
MBC: Metastatic Breast Cancer; MM: Multiple Myeloma; PLD: Pegylated Liposomal Doxorubicin.
























Figure 1 Comparison of odds ratio in CHF. The summary of OR wwas calculated using the fixed effect model. Squares are ORs of CHF for
separate trials Horizontal lines through the scores represent 95% CIs. The diamond represents the overall OR of CHF from the meta-analysis and
the corresponding 95% CIs. The studies that enrolled liposomal doxorubicin and conventional anthracyclines were separated into two groups for
this analysis. Abbreviations: CI: Confidence interval; OR: Odd ratio; CHF: Congestive Heart Failure.
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tropenia, alopecia, nausea and vomiting.
Different criteria were used to define the grade of tox-
icity. The majority of the trials (6 out of 9) used the
National Cancer Institute-Common Toxicity Criteria
(NCI-CTC). The remaining two trials used the WHO
criteria for toxicity and one trial used South West On-
cology Group (SWOG) toxicity scoring system. The
differences on the toxicity grading of the variables
were essentially unremarkable among the criteria [21].
The primary end points were the adverse effects: car-
diac toxicity with congestive cardiac failure and signifi-
cant reduction in the left ventricular ejection fraction
(LVEF) were entered in separate arms. The information
about the cumulative dose and cardiac toxicity was
extrapolated in a separate excel sheet. Four out of the
nine studies provided the data about the cumulative
doses at which cardiac toxicity was developed. Analysis
of cardiotoxicity included comparison of the proportion
of patients in each treatment group who developed car-
diotoxicity (by protocol specified cardiac event) at any
time during the study, as well as comparison of the
mean percentage change in LVEF from baseline.Figure 2 Comparison of odds ratio in palmar-plantar erythrodysesthe
calculated using the random effect model. Squares are ORs of PPE/HFS for
The diamond represents the overall OR of PPE/HFS from the meta-analysis
indicates the trial with highest OR. The studies that enrolled liposomal dox
groups for this analysis. Abbreviations: CI: Confidence interval; OR: Odd raThe hematology toxicities (anemia, leukopenia, neu-
tropenia and thrombocytopenia) were extracted to four
variables representing the grades of toxicity. The infor-
mation of the different grades of hematology toxicity
was not available in two of the trials. We analyzed the
number of the incidence of toxicity of any grade giving
specific importance to the grade toxicity.
There is difference in the grading of alopecia between
the WHO and NCI- CTC criteria. Alopecia, either par-
tial or complete, was analyzed as one variable.
The nausea and vomiting were included as one vari-
able. Two studies did not include the information about
nausea and vomiting. Four out of 9 studies did not have
grading for toxicity. Toxicity of all grades was therefore
considered as a single variable.
Statistical analysis
We performed the meta- analysis using the statistical
software ‘Stata’ 10 version (statistics and Data created by
Stata corp.). The existence of heterogeneity was tested
using the Chi square statistics. The heterogeneity was
quantified using the I-squared. For those variables with
high heterogeneity(p<0.05 for I-squared analysis), thesia (PPE)/Hand foot syndrome (HFS). The summary of OR was
separate trials. Horizontal lines through the squares represent 95% CIs.
and the corresponding 95% CIs. The horizontal line with an arrow
orubicin and conventional anthracyclines were separated into two
tio; PPE.
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Otherwise, fixed- effect model was used for the data
analysis. We calculated the odds ratio (OR) with 95%
confidence intervals (CIs) from the data extracted from
the original studies separately. The overall ORs were cal-
culated from the pooled data. We eliminated studies if
the data were not available for a particular variable.
Results
Characteristics of the studies
Nine randomized controlled trials that enrolled a total of
2220 patients were selected for the meta-analysis
(Table 1). 1112 patients were treated with liposome
encapsulated anthracyclines, including 666 who received
PLD, 330 who received LD, and 116 who received lipo-
somal daunorubicin. 1108 patients received the conven-
tional anthracyclines, including 80 who received
epirubicin, and 1028 who received doxorubicin. The trials
included four metastatic breast cancer trials, two multiple
myeloma trials, two AIDS-related soft tissue sarcoma
trials and one metastatic soft tissue sarcoma trials. Five of
the studies used Pegylated liposomal formulation DoxilW/Figure 3 Comparison of odds ratio in alopecia. The summary of OR wa
alopecia for separate trials. Horizontal lines through the squares represent 9
meta-analysis and the corresponding 95% CIs. The horizontal line with an a
liposomal doxorubicin and conventional anthracyclines were separated into
OR: Odd ratio..CAELYX and doxorubicin, four trials used non- pegylated
liposomal formulations (Myocet™/Liposomal Daunorubi-
cin) and conventional anthracyclines.
Cardiotoxicity
The cardiotoxicity (Figure 1) was higher with the doxo-
rubicin group in five trails, whereas three other trials
[14,25,26] did not show significant difference in cardiac
toxicity in both doxorubicin and liposomal doxorubicin
group. One trial did not report data on cardiac toxicity
and therefore was not included for analysis of the cardi-
otoxicity [22]. The median cumulative dose of the doxo-
rubicin in both forms was reported in six of the eight
trials analyzed. The median cumulative dose is higher with
the liposomal formulation in three of the trials [22,23,27],
lower in one trial [14] and same in two trials [16,24].
Three studies [14,16,26] compared the CHF or change
in LVEF based on the cumulative dose of anthracyclines.
In the study by Chan et al., the number of patients with
decrease in LVEF under a cumulative dose of <450 mg/
m2 were 5 and 8 for liposomal doxorubicin and epirubicin,
respectively. The change in LV function and CHF aboves calculated using the random effect model. Squares are ORs of
5% CIs. The diamond represents the overall OR of alopecia from the
rrow indicates the trial with highest OR. The studies that enrolled
two groups for this analysis. Abbreviations: CI: Confidence interval;
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with liposomal doxorubicin in O’Brien [14] and Batist [16]
studies. In the study by Batist et al., the estimated median
cumulative life time dose for cardiac toxicity was
2220 mg/m2 for the liposomal group and 480 mg/m2 for
the non liposomal group.
The odds ratio for the study conducted by Chan [26]
and Dimopoulos [25] were 1.14 and 1.45, respectively,
which is in favor of the non liposomal arm. The odds
ratios of six trials were in favor of the liposomal arm.
The pooled analyses were statistically significantly in
favor of the liposomal arm compared with the conven-
tional anthracyclines. The combined odds ratio for the
pooled result is 0.335 (95% CI (0.238–0.471, p = 0.086).
Palmar-plantar erythrodysesthesia (PPE)/hand-foot
syndrome
Five trials used pegylated liposomal doxorubicin. Four trials
used non pegylated liposomal anthracyclines (Figure 2).
The odds ratios for PPE in five trials were in favor of the
liposomal arm, the other four trials favored of the non-
liposomal anthracyclines. The combined odds ratio of theFigure 4 Comparison of odds ratio in neutropenia. The summary of OR
neutropenia for separate trials. Horizontal lines through the squares represe
from the meta-analysis and the corresponding 95% CIs. The studies that en
separated into two groups for this analysis. Abbreviations: CI: Confidencetrials were 1.08 (95% CI 0.11-10.30, p=0.947). Therefore,
the overall result of the nine trials did not show statistically
significant advantage of conventional anthracyclines over
liposomal preparations in PPE events.
Alopecia
The incidence of alopecia (Figure 3) showed consistent
results in 5 studies, whereas three studies showed no sig-
nificant difference in the incidence of alopecia. The trials
[14,23-25,27] showed significantly lower incidence of
alopecia. All these trials compared PLD with doxorubi-
cin. The three trials [8,16,26] that compared myocet
with conventional anthracyclines failed to show a signifi-
cant difference in the alopecia incidence. The overall
odds ratio from the pooled analysis was 0.25 (95% CI
0.10–0.62, p = 0.003).
Neutropenia
The incidence was counted for all grades of neutropenia.
The odds ratios of eight of the nine trials are in favor of
the liposomal doxorubicin (Figure 4). One study showed
similar toxicity on both arms. The pooled result is inwas calculated using the random effect model. Squares are ORs of
nt 95% CIs. The diamond represents the overall OR of neutropenia
rolled liposomal doxorubicin and conventional anthracyclines were
interval; OR: Odd ratio.
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0.62 (95% CI is 0.45–0.85, p = 0.003).Febrile neutropenia
The odds ratios of all 9 studies were analyzed. The odds
ratios of Chan, Dimpoulos, Gill, Harris and Northfelt
studies were in favor of the non liposomal anthracyclines.
The odds ratios of Batist, Judson, Northfelt and Rifkin
studies were in favor of the liposomal arm. The overall
OR for the pooled analysis of the nine trials was 0.89 (95%
CI 0.55–1.44, p = 0.639), making both arms essentially
similar adverse events of febrile neutropenia (Figure 5).
The other hematological toxicities anemia and
thrombocytopenia were also in favor of the liposomal
arm. The odd ratios of anemia and thrombocytopenia
were 0.89(CI; 0.71–1.12) and 0.87(CI; 0.61–1.25) re-
spectively. The incidence of nausea and vomiting was
less with the liposomal arm with an odd ratio of 0.79
(CI; 0.66–0.96).Figure 5 Comparison of odds ratio in febrile neutropenia. The summa
ORs of febrile neutropenia for separate trials. Horizontal lines through the s
Febrile Neutropenia from the meta-analysis and the corresponding 95% CI
The studies that enrolled liposomal doxorubicin and conventional anthracy
Abbreviations: CI: Confidence interval; OR: Odd ratio.Discussion
This meta-analysis included nine randomized controlled
trials comparing liposomal and conventional anthracyclines.
Previous studies [28] have shown that the incidence of
anthracycline induced CHF is directly proportional to
the cumulative dose of anthracyclines. Northfelt, O’Brien
and Batist plotted the relationship of cumulative dose of
liposomal anthracyclines and conventional anthracy-
clines [14,16,23]. In this meta-analysis, the odds ratio
reveals the incidence of cardiotoxicity to be significantly
lower with the liposomal anthracyclines. The heterogen-
eity of the studies was low and the I² showed moderate
heterogeneity for the cardiac toxicity. This study there-
fore confirms that the liposomal anthracyclines offer an
alternative to conventional anthracyclines for patients
with previous history of cardiac disease, elderly patients,
and prior use of anthracyclines who are at high risk to
develop cardiac toxicity. The safety profile with high cu-
mulative dose range of liposomal anthracyclines favors
the use of liposomal anthracyclines on patients whory of OR was calculated using the random effect model. Squares are
quares represent 95% CIs. The diamond represents the overall OR of
s. The horizontal line with an arrow indicates the trial with highest OR.
clines were separated into two groups for this analysis.
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safety profile of the liposomal formulations of anthracy-
clines suggests the potential to use it in combination
with trastuzumab in HER2 positive breast cancer.
The incidence of hematological toxicity of all grades
was lower with liposomal anthracyclines. The incidences
of neutropenia were significantly lower with liposomal
anthracyclines, although there were no significant differ-
ences in febrile neutropenia. The lower incidence of
myelosuppression makes the liposomal anthracyclines
particularly more desirable for elderly patients.
PPE is a dose limiting toxicity of pegylated liposomal
doxorubicin, doxil, which is the only liposomal doxo-
rubicin approved in USA, even though the meta-analysis
did not show significant differences in PPE.
The main limitations of the study are the heterogen-
eity of study groups. Though there was no difference
within the study in each group, there were variations
among different studies based on various factors. The
primary cancer treated was metastatic breast cancer in
four trials, multiple myeloma in two trials, AIDS related
Kaposi sarcoma in two trials and metastatic soft tissue
sarcoma in one trial. Due to the different tumor types,
the study drugs varied in the dose, frequency and num-
ber of treatment. However, the intergroup variations
have a limited effect on our meta-analysis due to the fact
that each trial is randomized and well controlled. There
are no variations among the two groups within the stud-
ies. The existence of heterogeneity among the study
group was evaluated using the chi-squared analysis. The
extent of heterogeneity was assessed using the I-squared
analysis. Moderate to high heterogeneity was noted
among the study groups. To minimize the bias, we used
random effects models for the studies with high hetero-
geneity, as recommended and performed by many statis-
ticians and meta-analysis publications [29-31].Conclusions
Liposomal doxorubicin and pegylated liposomal doxo-
rubicin demonstrated favorable toxicity profiles with bet-
ter cardiac safety and less myelosuppression, alopecia,
nausea and vomiting compared with the conventional
antracyclines. The better therapeutic index of liposomal
anthracyclines without compromising the efficacy makes
it a favorable choice over conventional anthracyclines in
elderly patients, patients with risk factors for cardiac dis-
ease and patients with prior use of anthracylines.Competing interests
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